Q2 FY26 results: PAT up 20%, revenue up 8% YoY

Revenue DeclineExceptional ItemResults View source PDF Explain this filing

SANOFI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.2%Reaction day

₹3395.00

prior close

₹3411.20

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.3%-3.5% vs market

Pharmaceuticals peers, median of 165sector-0.0%-2.2% vs sector

On the reaction day the stock moved 3.5 pts less than Nifty Microcap 250 and 2.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.2

10m

-2.5

15m

-2.1

30m

-1.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.2+1.3-3.5-0.0-2.2

Next day

-1.2+1.6-2.8+0.2-1.4

-1.3+1.7-3.0+0.4-1.7

-1.9+1.6-3.5+1.1-3.0

-2.8+1.5-4.2+1.2-4.0

-4.8+1.8-6.6+1.0-5.8

-4.7+2.1-6.8+0.5-5.2

15d

-6.1+3.2-9.2+0.2-6.2

-8.1+3.7-11.8+1.7-9.8

-11.0+1.1-12.2+1.2-12.2

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sanofi India posted Q2 FY26 revenue of Rs 437.7 cr, up 7.7% YoY. PAT grew 20% to Rs 83.5 cr. PBT margin improved to 27% from 24%, aided by 5% lower operating expenses. Insulin portfolio grew 14%; public sector sales jumped 70%. H1 revenue dipped 3.4% YoY to Rs 910 cr, while H1 PAT eased marginally to Rs 186.1 cr.

Likely market impact

Strong quarterly earnings with margin expansion and double-digit growth in core diabetes portfolio signal healthy operational momentum.